Androgen deprivation therapy may be linked to increased risk of dementia
BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5572 (Published 17 October 2016) Cite this as: BMJ 2016;355:i5572- Jacqui Wise
- London
Androgen deprivation therapy (ADT), a common treatment for prostate cancer, may be associated with an increased risk of dementia, new research in JAMA Oncology has found.1
Androgen deprivation therapy is used to reduce levels of androgens as they stimulate prostate cancer cells to grow. The approach has shown survival benefit in some patients but has also been associated with adverse health effects—for example, growing evidence supports a link between ADT and neurocognitive dysfunction.
The researchers …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.